Program
Filgrastim
Also written as “filgrastim”, “Neupogen (filgrastim)” and “Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous”.
Its studies are mostly in Neutropenia · Breast Neoplasms · ST Elevation Myocardial Infarction · Multiple Myeloma · Lymphoma, Non-Hodgkin, led by 15 companies.
Drug pageFilgrastim: every studyMany companies study it; this page follows only the 27 they lead. All 304 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgenits history only | 50 open or running | phase 2since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Pfizerits history only | 50 open or running | phase 2since Nov 5, 2013 | Nov 5, 2013 | none ahead |
| Biocadits history only | 30 open or running | phase 3since Apr 2, 2014 | Mar 30, 2012 | none ahead |
| Dong-A STits history only | 20 open or running | phase 3since Nov 10, 2017 | Mar 22, 2016 | none ahead |
| Novartisits history only | 20 open or running | phase 4since May 8, 2013 | Jan 13, 2012 | none ahead |
| Axaron Bioscienceits history only | 10 open or running | phase 2since Aug 18, 2005 | Aug 18, 2005 | none ahead |
| Azidus Brasilits history only | 10 open or running | phase 1since Mar 6, 2012 | Mar 6, 2012 | none ahead |
| BioGeneric Pharmaits history only | 11 open or running | phase 1since Oct 4, 2026 | Oct 4, 2026 | Apr 7, 2027phase 1 · NCT07877467 |
| Clinique Ovoits history only | 10 open or running | phase 3since Mar 19, 2014 | Mar 19, 2014 | none ahead |
| CSLits history only | 10 open or running | phase 1since May 31, 2019 | May 31, 2019 | none ahead |
| Dong-A Pharmaceutical | 10 open or running | phase 1since Mar 15, 2013 | Mar 15, 2013 | none ahead |
| Eurofarma Laboratoriosits history only | 10 open or running | phase 3since Mar 2, 2010 | Mar 2, 2010 | none ahead |
| Hangzhou Jiuyuan Gene Engineeringits history only | 10 open or running | phase 2since Aug 6, 2013 | Aug 6, 2013 | none ahead |
| Proteonomixits history only | 10 open or running | phase 1since Oct 11, 2012 | Oct 11, 2012 | none ahead |
| Sygnis Bioscience GmbH & Co KGits history only | 10 open or running | phase 2since Jun 24, 2009 | Jun 24, 2009 | none ahead |
Also a collaborator on its studies: Celerion, Sandoz and Numoda.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Dong-A Pharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 15, 2013First study: phase 1 study in Diabetic NeuropathiesFirst studyNCT01820715 · 31 enrolled · Korea, Republic of
TargetBeta
“Granulocyte colony stimulating factor receptor agonist”ChEMBL 37, by rule
Other programs on CSF3R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| pegfilgrastimrule | Amgen | phase 4 | 52 |
| anumigilimabrule | CSL | phase 2 | 4 |
Studies
The one study Dong-A Pharmaceutical leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01820715Diabetic Neuropathies · Korea, Republic of | 1 | Completed | Apr 2013 | 31 |
How it is read
Names in the registry
- “Filgrastim”, 11 entries
- “filgrastim”, 4 entries
- “Neupogen (filgrastim)”, 2 entries
- “Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous”, 2 entries
- “Leucostim®”, 2 entries
Codes read as this program: DA3030.
Conditions, from the studies’ own filings
- Neutropenia, 7 studies
- Breast Neoplasms, 3 studies
- ST Elevation Myocardial Infarction, 2 studies
- Multiple Myeloma, 2 studies
- Lymphoma, Non-Hodgkin, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.